Is there a Bearish outlook for MacroGenics, Inc. (NASDAQ:MGNX) this week?

Investors sentiment decreased to 0.92 in 2019 Q2. Its down 1.23, from 2.15 in 2019Q1. It dived, as 28 investors sold MacroGenics, Inc. shares while 34 reduced holdings. 12 funds opened positions while 45 raised stakes. 39.29 million shares or 2.04% less from 40.11 million shares in 2019Q1 were reported.
Granahan Invest Mgmt Incorporated Ma has invested 0.18% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX). 26,261 were reported by Credit Suisse Ag. 200,289 were accumulated by Bankshares Of Ny Mellon Corporation. Gsa Capital Prtn Llp holds 0.03% or 15,469 shares. Massachusetts Fincl Ma holds 0% of its portfolio in MacroGenics, Inc. (NASDAQ:MGNX) for 75,573 shares. Loring Wolcott Coolidge Fiduciary Advsrs Limited Liability Partnership Ma, Massachusetts-based fund reported 213 shares. 10,000 were reported by Northeast Fincl Consultants. Victory Cap Mgmt Inc, a Ohio-based fund reported 106,600 shares. Geode Cap Management Lc holds 0% or 598,129 shares. Prelude Cap Mgmt Ltd has 0% invested in MacroGenics, Inc. (NASDAQ:MGNX) for 272 shares. Fmr Limited Liability Corporation holds 0% or 1.28M shares in its portfolio. Jpmorgan Chase Communications holds 0% or 26,886 shares in its portfolio. Signaturefd Ltd Liability stated it has 45 shares or 0% of all its holdings. State Board Of Administration Of Florida Retirement System reported 24,020 shares. Susquehanna Intll Grp Llp holds 0% or 73,507 shares.

MacroGenics, Inc. (NASDAQ:MGNX) Ratings Coverage

Among 2 analysts covering Macrogenics (NASDAQ:MGNX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Macrogenics has $29 highest and $2500 lowest target. $27’s average target is 137.26% above currents $11.38 stock price. Macrogenics had 3 analyst reports since April 17, 2019 according to SRatingsIntel. The stock of MacroGenics, Inc. (NASDAQ:MGNX) has “Buy” rating given on Thursday, August 1 by Stifel Nicolaus. Below is a list of MacroGenics, Inc. (NASDAQ:MGNX) latest ratings and price target changes.

01/08/2019 Broker: Stifel Nicolaus Rating: Buy Old Target: $29.0000 New Target: $25.0000 Maintain
03/05/2019 Broker: Inc. – Common Stock Rating: Wedbush 26.0000
17/04/2019 Broker: Credit Suisse Rating: Outperform New Target: $29 Initiates Coverage On

The stock increased 0.53% or $0.06 during the last trading session, reaching $11.38. About 300,947 shares traded. MacroGenics, Inc. (NASDAQ:MGNX) has declined 28.01% since October 12, 2018 and is downtrending. It has underperformed by 28.01% the S&P500.

MacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company has market cap of $556.41 million. The companyÂ’s advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It currently has negative earnings. It also develops Enoblituzumab, a monoclonal antibody, which is in Phase 1 clinical trial as monotherapy in multiple solid tumor types, as well as in combination therapy with either an anti-PD-1 antibody or an anti-CTLA-4 antibody; Flotetuzumab, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Duvortuxizumab, a DART molecule that targets both CD19 and CD3; MGD009, a molecule in its B7-H3 franchise; MGA012, a monoclonal antibody, which targets PD-1; MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; and MGC018, a B7-H3 antibody-drug conjugate.

More notable recent MacroGenics, Inc. (NASDAQ:MGNX) news were published by: Businesswire.com which released: “IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MacroGenics, Inc. and Encourages Investors with Losses in Excess of $100000 to Contact the Firm – Business Wire” on September 14, 2019, also Seekingalpha.com with their article: “MacroGenics: Strong Fundamentals Coupled With Major Catalysts Ahead – Seeking Alpha” published on August 23, 2019, Businesswire.com published: “Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against MacroGenics, Inc. (NASDAQ: MGNX) and Encourages MacroGenics Investors to Contact the Firm – Business Wire” on September 16, 2019. More interesting news about MacroGenics, Inc. (NASDAQ:MGNX) were released by: Globenewswire.com and their article: “LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50000 In MacroGenics, Inc. To Contact The Firm – GlobeNewswire” published on September 17, 2019 as well as Globenewswire.com‘s news article titled: “MacroGenics Announces Removal of Partial Clinical Hold on MGD009 Program by FDA – GlobeNewswire” with publication date: January 25, 2019.

MacroGenics, Inc. (NASDAQ:MGNX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.